Orthocell (ASX $OCC) has today released positive clinical data for its OrthoATI™ tendon program, which shows that OrthoATI™ is statistically more effective than the current standard of care (corticosteroid injection) for treatment of rotator cuff tendinopathy with intrasubstance tendon tear.
Ortho-ATI® Update
Orthocell (ASX $OCC) has today released an update on its Ortho-ATI™ rotator cuff tendon study – the database is now locked and the Company is track to report the highly anticipated top line results in Q4 this calendar year.
This study was designed to assess the effectiveness of Ortho-ATI™, compared to corticosteroids, as a non-surgical treatment for a complex, hard-to-treat clinical problem.
Should the study meet its objectives, Orthocell is well positioned to deliver the first FDA approved injectable cell therapy in orthopaedics for the treatment of chronic tendon injuries in a rotator cuff market estimated at around US$2.8b per annum.
Orthocell featured as a Case Study in the Australian Regenerative Medicine Therapies Report
Orthocell’s CelGro™ technology has been featured as one of only four case studies in the recent Australian Regenerative Medicine Therapies report.
Investor Presentation | Canaccord Genuity South-West Connect ASX Showcase
Orthocell MD, Paul Anderson, presented at the Canaccord Genuity South-West Connect ASX Showcase today to share the latest news and developments for the Company’s Ortho-ATI™ and CelGro™ platform technologies.
Orthocell (ASX:OCC) announces positive data on CelGro collagen rope for ACL repair
Orthocell has been featured in The Market Herald, following our announcement of positive data from a pre-clinical study for anterior cruciate ligament (ACL) reconstruction.
Orthocell (ASX:OCC) granted patents in Canada and Hong Kong for CelGro
Orthocell has been featured in The Market Herald, following our announcement of patents granted in Canada and Hong Kong for CelGro.
Video | Proactive Investors – September 2021
Orthocell CEO and Managing Director Paul Anderson spoke with Andrew Scott from Proactive Investors about passing a key milestone in the OrthoATI™ rotator cuff tendon study.
Orthocell’s (ASX:OCC) final patient completes treatment in tendon regeneration study
Orthocell has been featured in The Market Herald, highlighting the follow-up announcement from our OrthoATI™ rotator cuff tendon regeneration study.
Video | Proactive Investors – Orthocell highlights potential for CelGro in treatment of lymphedema
Orthocell CEO and Managing Director Paul Anderson speaks to Proactive after announcing a breakthrough tissue engineering study, combining CelGro™ with lymphatic and blood vessel cells to create functional lymphatic tissue, has been published in the Proceedings of the National Academy of Sciences of the United States of America (PNAS).
Orthocell (ASX:OCC) has breakthrough tissue engineering study published in US
Orthocell has been featured in The Market Herald, following the publication of our breakthrough tissue engineering study in the peer-reviewed journal “Proceedings of the National Academy of Sciences of the United States of America”.